



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A7483

Xiao-Mai ZHOU

Appln. No.: 09/580,523

Group Art Unit: 1642

Confirmation No.: 8284

Examiner: Minh Tam Davis

Filed: May 30, 2000

For: COMPOUNDS AND METHODS FOR REGULATING APOPTOSIS, AND METHODS OF MAKING AND SCREENING FOR COMPOUNDS THAT REGULATE APOPTOSIS

**STATEMENT OF SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on

April 27, 2006:

**REMARKS**

An Examiner's Interview Summary Record (PTO-413) was mailed April 27, 2006.

During the interview, the following was discussed: Claim language that would obviate the 112, first paragraph rejection.

1. Brief description of exhibits or demonstration: None
2. Identification of claims discussed: None. New wording for claims was proposed.
3. Identification of art discussed: None.
4. Identification of principal proposed amendments:

STATEMENT OF SUBSTANCE OF INTERVIEW  
U.S. Patent Application No.: 09/580,523

Attorney Docket No.: A7483

Applicants proposed to present claims to a polypeptide comprising SEQ ID NO:1 wherein ser-118 is replaced by alanine or glycine. The Examiner stated that such would be allowable provided support was present for glycine.


Applicants proposed to present claims to a polypeptide comprising at least the disclosed fragments containing the BH3 domain wherein ser-118 is replaced by alanine or glycine. The Examiner stated that such claims would be considered if the claims also recited that the polypeptide has *in vitro* cell death promoting activity.

5. Brief Identification of principal arguments: None.
6. Indication of other pertinent matters discussed: None.
7. Results of Interview: See item 4 above.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

**It is believed that no petition or fee is required.** However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

  
\_\_\_\_\_  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
**23373**  
CUSTOMER NUMBER

Date: May 26, 2006